PubMed · 1986 · 22 citations · 18 references
Life SciencesImmunologyInfectious DiseasesHypersensitivityImmunizationVaccinologyAdaptive Immune ResponsesDelayed-type HypersensitivityImmune Response To VaccinationVaccinationVaccine ReactogenicityVaccine-preventable DiseasesDelayed Cutaneous HypersensitivityReactivityVaccine Candidate AntigensVaccine Characterization
A killed armadillo-derived Mycobacterium leprae vaccine was examined for its ability to induce a delayed-type hypersensitivity (DTH) response in purified protein derivative (PPD)-positive human volunteers living in a leprosy non-endemic country. Four groups of individuals aged between 23 and 28 years were given 1.5 x 10(7), 5 x 10(7), 1.5 x 10(8) and 5 x 10(8)M. leprae intradermally. A marked increase in reactivity to the M. leprae-derived skin test antigen (MLSA) was observed in the vaccinated groups receiving the three highest doses of vaccine while there was very little change observed in their PPD reactivity. No unacceptable side-effects attributable to the vaccine were observed. The killed armadillo-derived M. leprae vaccine thus appears to be able to induce a DTH response in man at doses which do not cause unacceptable side-effects.
18
Classification of leprosy according to immunity. A five-group system.
D.S. Ridley, W. H. Jopling · PubMed · 1966 · 2.5K citations
Lymphocyte suppression in leprosy induced by unique M. leprae glycolipid
Vijay Mehra, Patrick J. Brennan, Elsa Rada et al. · Nature · 1984 · 227 citations
Human T-cell clones recognize a major M. leprae protein antigen expressed in E. coli
Abu Salim Mustafa, Harvindar Kaur Gill, Audun Helge Nerland et al. · Nature · 1986 · 158 citations